Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes : Results from the CORONADO study
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
AIM: Patients with type 2 diabetes mellitus (T2DM) represent a high-risk population for both cardiovascular diseases and severe coronavirus disease 2019 (COVID-19). Recent studies have reported interactions between statin treatment and COVID-19-related outcomes. The study reported here specifically assessed the association between routine statin use and COVID-19-related outcomes in inpatients with T2DM.
METHODS: The Coronavirus-SARS-CoV-2 and Diabetes Outcomes (CORONADO) study was a nationwide observational study aiming to describe the phenotypic characteristics and prognosis of T2DM patients with COVID-19 admitted to 68 French hospitals between 10 March and 10 April 2020. The composite primary outcome comprised tracheal intubation and/or death within 7 and 28 days of admission. The association between statin use and outcomes was estimated by logistic regression analysis after applying inverse probability of treatment weighting (IPTW) using a propensity score-weighting approach.
RESULTS: Of the 2449 patients with T2DM (881 women, 1568 men; aged 70.9 ± 12.5 years) suitable for analysis, 1192 (49%) were using statin treatment before admission. In unadjusted analyses, patients using statins had rates of the primary outcome similar to those of non-users within both 7 (29.8% vs 27.0%, respectively; P = 0.1338) and 28 days (36.2% vs 33.8%, respectively; P = 0.2191) of admission. However, mortality rates were significantly higher in statin users within 7 (12.8% vs 9.8%, respectively; P = 0.02) and 28 days (23.9% vs 18.2%, respectively; P < 0.001). After applying IPTW, significant associations were observed with statin use and the primary outcome within 7 days (OR [95% CI]: 1.38 [1.04-1.83]) and with death within both 7 (OR [95% CI]: 1.74 [1.13-2.65]) and 28 days (OR [95% CI]: 1.46 [1.08-1.95]).
CONCLUSION: Routine statin treatment is significantly associated with increased mortality in T2DM patients hospitalized for COVID-19.
| Errataetall: |
CommentIn: Diabetes Metab. 2021 May;47(3):101250. - PMID 33744398 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Diabetes & metabolism - 47(2021), 2 vom: 15. März, Seite 101202 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cariou, Bertrand [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 25.03.2021 Date Revised 22.02.2022 published: Print-Electronic CommentIn: Diabetes Metab. 2021 May;47(3):101250. - PMID 33744398 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diabet.2020.10.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316604658 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316604658 | ||
| 003 | DE-627 | ||
| 005 | 20231225161440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabet.2020.10.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316604658 | ||
| 035 | |a (NLM)33091555 | ||
| 035 | |a (PII)S1262-3636(20)30153-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cariou, Bertrand |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes |b Results from the CORONADO study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2021 | ||
| 500 | |a Date Revised 22.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Diabetes Metab. 2021 May;47(3):101250. - PMID 33744398 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a AIM: Patients with type 2 diabetes mellitus (T2DM) represent a high-risk population for both cardiovascular diseases and severe coronavirus disease 2019 (COVID-19). Recent studies have reported interactions between statin treatment and COVID-19-related outcomes. The study reported here specifically assessed the association between routine statin use and COVID-19-related outcomes in inpatients with T2DM | ||
| 520 | |a METHODS: The Coronavirus-SARS-CoV-2 and Diabetes Outcomes (CORONADO) study was a nationwide observational study aiming to describe the phenotypic characteristics and prognosis of T2DM patients with COVID-19 admitted to 68 French hospitals between 10 March and 10 April 2020. The composite primary outcome comprised tracheal intubation and/or death within 7 and 28 days of admission. The association between statin use and outcomes was estimated by logistic regression analysis after applying inverse probability of treatment weighting (IPTW) using a propensity score-weighting approach | ||
| 520 | |a RESULTS: Of the 2449 patients with T2DM (881 women, 1568 men; aged 70.9 ± 12.5 years) suitable for analysis, 1192 (49%) were using statin treatment before admission. In unadjusted analyses, patients using statins had rates of the primary outcome similar to those of non-users within both 7 (29.8% vs 27.0%, respectively; P = 0.1338) and 28 days (36.2% vs 33.8%, respectively; P = 0.2191) of admission. However, mortality rates were significantly higher in statin users within 7 (12.8% vs 9.8%, respectively; P = 0.02) and 28 days (23.9% vs 18.2%, respectively; P < 0.001). After applying IPTW, significant associations were observed with statin use and the primary outcome within 7 days (OR [95% CI]: 1.38 [1.04-1.83]) and with death within both 7 (OR [95% CI]: 1.74 [1.13-2.65]) and 28 days (OR [95% CI]: 1.46 [1.08-1.95]) | ||
| 520 | |a CONCLUSION: Routine statin treatment is significantly associated with increased mortality in T2DM patients hospitalized for COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Outcomes | |
| 650 | 4 | |a Statins | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Goronflot, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Rimbert, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Boullu, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Le May, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Moulin, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Pichelin, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Potier, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Smati, Sarra |e verfasserin |4 aut | |
| 700 | 1 | |a Sultan, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Tramunt, Blandine |e verfasserin |4 aut | |
| 700 | 1 | |a Wargny, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Gourdy, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjadj, Samy |e verfasserin |4 aut | |
| 700 | 0 | |a CORONADO investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolism |d 1998 |g 47(2021), 2 vom: 15. März, Seite 101202 |w (DE-627)NLM086696130 |x 1878-1780 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:2 |g day:15 |g month:03 |g pages:101202 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diabet.2020.10.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 2 |b 15 |c 03 |h 101202 | ||